R&D channel feed

As­traZeneca's suc­ces­sor to Covid block­buster Evusheld suc­ceeds in Phase 3 tri­al

Last year
Coronavirus

J&J makes small I&I ac­qui­si­tion to en­ter com­pet­i­tive IL-13, TSLP are­na

Last year
Deals

Lil­ly touts topline late-phase da­ta for once-week­ly in­sulin in race to en­ter US mar­ket

Last year

Ex­clu­sive: Gas­tro­pare­sis biotech Cin­Dome se­cures $40M for path to piv­otal tri­al

Last year
Financing

Roche teas­es 'en­cour­ag­ing' Phase 1 da­ta for weight loss drug from $2.7B Car­mot buy­out

Last year

Re­searchers con­sid­er why We­govy pro­vides heart ben­e­fits be­yond weight loss

Last year

Bolt Bio­ther­a­peu­tics re­vamps as it drops lead can­cer as­set, changes CEO and trims head­count

Last year
People

Pli­ant touts ad­di­tion­al Phase 2a da­ta for oral IPF drug that’s al­ready in a piv­otal study

Last year

The End­points Slack in­ter­view: Sid­dhartha Mukher­jee on the doc­tor-writer world­view, AI, and the fu­ture of can­cer

Last year
AI
In Focus

Bay­er cuts 1,500 staffers com­pa­ny­wide in cam­paign to re­duce bu­reau­cra­cy

Last year
Pharma

No­vo Nordisk's We­govy helps keep weight off over four years, new analy­sis shows

Last year

Sh­iono­gi miss­es pri­ma­ry end­point in Phase 3 for Covid-19 an­tivi­ral

Last year
Coronavirus

No­vo clears Phase 3 he­mo­phil­ia A tri­al, plans to sub­mit ap­pli­ca­tion by year's end

Last year

Car­du­ri­on touts Phase 2 da­ta for PDE9 in­hibitor in heart fail­ure, plans for two more tri­als

Last year

Cy­to­ki­net­ics lifts cur­tain on Phase 3 afi­camten da­ta, com­mer­cial launch prep un­der­way

Last year
Pharma

Mer­ck winds down Phase 3 TIG­IT/PD-1 com­bo study due to safe­ty-re­lat­ed dropouts

Last year

Ex­ci­sion Bio­Ther­a­peu­tics’ at­tempt to gene ed­it HIV dis­ap­points. The com­pa­ny will now re­vamp vec­tor: #AS­GCT24

Last year
Cell/Gene Tx

Sci­en­tists and star­tups re­veal new gene in­ser­tion tech­niques, though much re­mains be­hind closed doors: #AS­GCT24

Last year
Startups
Cell/Gene Tx

iTeos to raise $120M; Xbrane and STA­DA to out-li­cense Lu­cen­tis biosim­i­lar

Last year
News Briefing

Tessera un­veils promis­ing in vi­vo gene edit­ing treat­ment for sick­le cell in an in­creas­ing­ly com­pet­i­tive field: #AS­GCT24

Last year
Cell/Gene Tx

Macro­Gen­ics in­ves­ti­gates three pa­tient deaths in Phase 2 prostate can­cer drug tri­al

Last year

Af­ter FTC scruti­ny of Sanofi deal, Maze finds a new Pompe part­ner in Sh­iono­gi

Last year
Deals
Pharma

Across two clin­i­cal tri­als, gene ther­a­py re­stores hear­ing in chil­dren deaf since birth: #AS­GCT24

Last year
Cell/Gene Tx

Rapt Ther­a­peu­tics winds down Phase 2 stud­ies of lead can­di­date in wake of clin­i­cal holds

Last year
First page Previous page 45464748495051 Next page Last page
A service from the Financial Times